Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer - Concepedia

Concepedia

Publication | Open Access

Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer

DOI Full Paper Access

149

Citations

25

References

2018

Year

Bernhard Grubmüller, Daniela Senn, Gero Kramer, Pascal Baltzer, David D‘Andrea, Karl Hermann Grubmüller, Markus Mitterhauser, Harald Eidherr, Alexander Haug, Wolfgang Wadsak,

European Journal of Nuclear Medicine and Molecular Imaging

Abstract

TTV on PSMA PET seems to be a reliable parameter for response assessment in mCRPC patients undergoing RLT and might overcome the limitations of RECIST in prostate cancer. Furthermore, the change in TTV was significantly associated with OS in our cohort.

References

	Year	Citations

Page 1